obesity drug news today glp-1 2025 sep 30 The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs Pharma Giants Bet on Next-Generation

A possibility for harm reduction As research on GLP-1RAs and AUD advances, it is becoming increasingly clear that these medications have the potential to reduce alcohol consumption

The latest TEXAIS results in 2023 were negative with a certain trend, which might be limited by the small sample size, short treatment duration and lack of medium to long-term therapeutic evaluation

Overall, if they can afford the medication, they are overwhelmingly thrilled, she said

For guidance on evaluating research peptide supplier quality, see our Research Peptides Sourcing Guide

Both GLP-1 agonists and Actos slow the decline of insulin production, which is a key reason for rising blood sugar levels over time, leading many with type 2 diabetes to start insulin therapy

[DOI] [PMC free article] [PubMed] [Google Scholar] 54.Burmeister MA, Brown JD, Ayala JE, Stoffers DA, Sandoval DA, Seeley RJ, et al